Literature DB >> 3123547

Pituitary function after orchiectomy in patients with or without earlier estrogen treatment for prostatic carcinoma.

R Tomić1.   

Abstract

Testosterone, FSH, LH and prolactin were measured before, and up to 36 months after orchiectomy in 62 patients with prostatic carcinoma; 36 were treated by primary orchiectomy, 10 by orchiectomy after prior estrogen treatment for less than 3 yr (short-term) and 16 for more than 3 yr (long-term). Before orchiectomy serum levels of testosterone, FSH and LH were significantly lower in estrogen-treated than in untreated patients. Following orchiectomy serum FSH and LH increased in all patients studied. However, long-term estrogen-treated patients had significantly lower FSH and LH both before orchiectomy and during the follow-up period than those treated by primary orchiectomy or orchiectomized after short-term estrogen treatment. In addition, in those long-term estrogen-treated patients, serum testosterone did not significantly decrease after orchiectomy, whereas in patients treated by primary orchiectomy or orchiectomized after short-term estrogen treatment serum testosterone fell significantly. At follow-up comparable levels of testosterone were found in the three patient groups studied. Prolactin levels did not differ significantly between the patient groups and were not elevated either before or after orchiectomy. It is suggested that patients with carcinoma of the prostate treated with estrogen for more than 3 yr have impaired, but slowly increasing, pituitary gland function, possibly caused by long-term effect of estrogen on the pituitary gland.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3123547     DOI: 10.1007/BF03348174

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  15 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Feedback regulation of circulating LRF concentrations in men.

Authors:  L E Seyler; S Reichlin
Journal:  J Clin Endocrinol Metab       Date:  1974-11       Impact factor: 5.958

3.  Plasma prolactin, GH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens.

Authors:  A R Boyns; E N Cole; M E Phillips; S G Hillier; E H Cameron; K Griffiths; M Shahmanesh; R C Feneley; M Hartog
Journal:  Eur J Cancer       Date:  1974-07       Impact factor: 9.162

4.  Adrenalectomy and hypophysectomy in advanced prostatic carcinoma.

Authors:  G Reynoso; G P Murphy
Journal:  Cancer       Date:  1972-04       Impact factor: 6.860

5.  Recovery of testicular and pituitary functions in adult male rats after cessation of short and long term estradiol treatment.

Authors:  R K Tcholakian; M Chowdhury; A K Chowdhury
Journal:  Biol Reprod       Date:  1978-09       Impact factor: 4.285

6.  Simplified, partially automated method for radioimmunoassay of human thyroid-stimulating, growth, luteinizing, and follicle stimulating hormones.

Authors:  W D Odell; P L Rayford; G T Ross
Journal:  J Lab Clin Med       Date:  1967-12

7.  Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.

Authors:  R Tomić
Journal:  Scand J Urol Nephrol Suppl       Date:  1983

8.  A radioimmunoassay for human prolactin.

Authors:  P Hwang; H Guyda; H Friesen
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

9.  Long-term effects of endocrine treatment on serum pituitary hormones in advanced prostatic carcinoma patients.

Authors:  O Lukkarinen; G L Hammond; M Kontturi; R Vihko
Journal:  Scand J Urol Nephrol       Date:  1981

10.  Testicular endocrine function after withdrawal of oestrogen treatment in patients with carcinoma of the prostate.

Authors:  R Tomić; B Bergman; J E Damber
Journal:  Br J Urol       Date:  1983-02
View more
  1 in total

Review 1.  Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?

Authors:  Piotr Zareba; Wilhelmina Duivenvoorden; Darryl P Leong; Jehonathan H Pinthus
Journal:  Ther Adv Urol       Date:  2015-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.